Amarin (AMRN) Competitors

Amarin has higher revenue and earnings than Seaport Therapeutics. Amarin is trading at a lower price-to-earnings ratio than Seaport Therapeutics, indicating that it is currently the more affordable of the two stocks.

Seaport Therapeutics has a net margin of 0.00% compared to Amarin's net margin of -14.56%. Seaport Therapeutics' return on equity of 0.00% beat Amarin's return on equity.

In the previous week, Seaport Therapeutics had 6 more articles in the media than Amarin. MarketBeat recorded 10 mentions for Seaport Therapeutics and 4 mentions for Amarin. Amarin's average media sentiment score of 0.86 beat Seaport Therapeutics' score of 0.06 indicating that Amarin is being referred to more favorably in the news media.

Seaport Therapeutics presently has a consensus target price of $38.57, indicating a potential upside of 112.51%. Amarin has a consensus target price of $13.00, indicating a potential upside of 8.06%. Given Seaport Therapeutics' stronger consensus rating and higher possible upside, research analysts clearly believe Seaport Therapeutics is more favorable than Amarin.

22.3% of Amarin shares are held by institutional investors. 4.2% of Amarin shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Amarin has higher revenue and earnings than Alto Neuroscience. Amarin is trading at a lower price-to-earnings ratio than Alto Neuroscience, indicating that it is currently the more affordable of the two stocks.

In the previous week, Amarin had 1 more articles in the media than Alto Neuroscience. MarketBeat recorded 4 mentions for Amarin and 3 mentions for Alto Neuroscience. Amarin's average media sentiment score of 0.86 beat Alto Neuroscience's score of 0.62 indicating that Amarin is being referred to more favorably in the media.

Alto Neuroscience has a net margin of 0.00% compared to Amarin's net margin of -14.56%. Amarin's return on equity of -0.20% beat Alto Neuroscience's return on equity.

22.3% of Amarin shares are held by institutional investors. 4.2% of Amarin shares are held by company insiders. Comparatively, 11.3% of Alto Neuroscience shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Amarin has a beta of 0.76, meaning that its share price is 24% less volatile than the broader market. Comparatively, Alto Neuroscience has a beta of 1.31, meaning that its share price is 31% more volatile than the broader market.

Amarin presently has a consensus price target of $13.00, suggesting a potential upside of 8.06%. Alto Neuroscience has a consensus price target of $37.25, suggesting a potential upside of 52.66%. Given Alto Neuroscience's stronger consensus rating and higher probable upside, analysts clearly believe Alto Neuroscience is more favorable than Amarin.

In the previous week, Cybin had 1 more articles in the media than Amarin. MarketBeat recorded 5 mentions for Cybin and 4 mentions for Amarin. Amarin's average media sentiment score of 0.86 beat Cybin's score of 0.77 indicating that Amarin is being referred to more favorably in the media.

Amarin has higher revenue and earnings than Cybin. Amarin is trading at a lower price-to-earnings ratio than Cybin, indicating that it is currently the more affordable of the two stocks.

22.3% of Amarin shares are held by institutional investors. Comparatively, 17.9% of Cybin shares are held by institutional investors. 4.2% of Amarin shares are held by insiders. Comparatively, 15.0% of Cybin shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Amarin currently has a consensus target price of $13.00, suggesting a potential upside of 8.06%. Cybin has a consensus target price of $46.33, suggesting a potential upside of 292.66%. Given Cybin's stronger consensus rating and higher probable upside, analysts clearly believe Cybin is more favorable than Amarin.

Cybin has a net margin of 0.00% compared to Amarin's net margin of -14.56%. Amarin's return on equity of -0.20% beat Cybin's return on equity.

Amarin has a beta of 0.76, meaning that its share price is 24% less volatile than the broader market. Comparatively, Cybin has a beta of 0.53, meaning that its share price is 47% less volatile than the broader market.

In the previous week, Amarin had 4 more articles in the media than Theravance Biopharma. MarketBeat recorded 4 mentions for Amarin and 0 mentions for Theravance Biopharma. Amarin's average media sentiment score of 0.86 beat Theravance Biopharma's score of 0.00 indicating that Amarin is being referred to more favorably in the news media.

Theravance Biopharma currently has a consensus price target of $19.40, indicating a potential upside of 13.92%. Amarin has a consensus price target of $13.00, indicating a potential upside of 8.06%. Given Theravance Biopharma's higher probable upside, analysts clearly believe Theravance Biopharma is more favorable than Amarin.

Theravance Biopharma has higher earnings, but lower revenue than Amarin. Amarin is trading at a lower price-to-earnings ratio than Theravance Biopharma, indicating that it is currently the more affordable of the two stocks.

99.1% of Theravance Biopharma shares are held by institutional investors. Comparatively, 22.3% of Amarin shares are held by institutional investors. 7.7% of Theravance Biopharma shares are held by company insiders. Comparatively, 4.2% of Amarin shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Theravance Biopharma has a beta of 0.25, indicating that its share price is 75% less volatile than the broader market. Comparatively, Amarin has a beta of 0.76, indicating that its share price is 24% less volatile than the broader market.

Theravance Biopharma has a net margin of 51.58% compared to Amarin's net margin of -14.56%. Amarin's return on equity of -0.20% beat Theravance Biopharma's return on equity.